AVALIDE Drug Patent Profile

Which patents cover Avalide, and what generic alternatives are available?

Avalide is a drug marketed by Sanofi Aventis Us and is included in one NDA.

The generic ingredient in AVALIDE is hydrochlorothiazide; irbesartan. There are thirty-two drug master file entries for this compound. Thirteen suppliers are listed for this compound. Additional details are available on the hydrochlorothiazide; irbesartan profile page.

Summary for AVALIDE

US Patents:	0
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	4
Clinical Trials:	3
Patent Applications:	131
Drug Prices:	Drug price information for AVALIDE
What excipients (inactive ingredients) are in AVALIDE?	AVALIDE excipients list
DailyMed Link:	AVALIDE at DailyMed

See drug prices for AVALIDE

Recent Clinical Trials for AVALIDE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Bayer	Phase 3
Roxane Laboratories	N/A

See all AVALIDE clinical trials

Pharmacology for AVALIDE

Drug Class	Angiotensin 2 Receptor Blocker Thiazide Diuretic
Mechanism of Action	Angiotensin 2 Receptor Antagonists
Physiological Effect	Increased Diuresis

Paragraph IV (Patent) Challenges for AVALIDE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
AVALIDE	Tablets	hydrochlorothiazide; irbesartan	300 mg/25 mg	020758	1	2006-06-06
AVALIDE	Tablets	hydrochlorothiazide; irbesartan	150 mg/12.5 mg and 300 mg/12.5 mg	020758	1	2004-11-10

US Patents and Regulatory Information for AVALIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sanofi Aventis Us	AVALIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	020758-001	Sep 30, 1997		DISCN	Yes	No
Sanofi Aventis Us	AVALIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	020758-004	Mar 15, 2005		DISCN	Yes	No
Sanofi Aventis Us	AVALIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	020758-002	Sep 30, 1997	AB	RX	Yes	Yes

Expired US Patents for AVALIDE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Sanofi Aventis Us	AVALIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	020758-001	Sep 30, 1997	5,270,317*PED
Sanofi Aventis Us	AVALIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	020758-003	Aug 31, 1998	5,994,348*PED
Sanofi Aventis Us	AVALIDE	hydrochlorothiazide; irbesartan	TABLET;ORAL	020758-004	Mar 15, 2005	5,994,348*PED

EU/EMA Drug Approvals for AVALIDE

Company	Drugname	Inn	Product Number / Indication	Status	Generic	Biosimilar	Orphan	Marketing Authorisation	Marketing Refusal
sanofi-aventis groupe	Irbesartan Hydrochlorothiazide Zentiva (previously Irbesartan Hydrochlorothiazide Winthrop)	irbesartan, hydrochlorothiazide	EMEA/H/C/000783Treatment of essential hypertension. This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	no	no	no	2007-01-18
Sanofi Winthrop Industrie	Karvezide	irbesartan, hydrochlorothiazide	EMEA/H/C/000221Treatment of essential hypertension.This fixed-dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	no	no	no	1998-10-16
Sanofi Winthrop Industrie	CoAprovel	irbesartan, hydrochlorothiazide	EMEA/H/C/000222Treatment of essential hypertension. This fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on irbesartan or hydrochlorothiazide alone.	Authorised	no	no	no	1998-10-14

International Patents for AVALIDE

See the table below for patents covering AVALIDE around the world.

Country	Patent Number	Title	Estimated Expiration
Taiwan	442301
Finland	103407
Australia	702651

Supplementary Protection Certificates for AVALIDE

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0454511	SPC/GB99/008	United Kingdom		PRODUCT NAME: 2-N-BUTYL-4-SPIROCYCLOPENTANE-1-((2'-(TETRAZOL-5-YL)BIPHENYL-4-YL)METHYL)-2-IMIDAZOLIN-5-ONE)(GENERIC NAME IRBESARTAN) OPTIONALLY IN THE FORM OF ONE OF ITS SALTS AND HYDROCHLOROTHIAZIDE; REGISTERED: UK EU/1/98/086/001 19981015; UK EU/1/98/086/002 19981015; UK EU/1/98/086/003 19981015; UK EU/1/98/086/004 19981015; UK EU/1/98/086/005 19981015; UK EU/1/98/086/006 19981015
0443983	C00443983/03	Switzerland		PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009
0480717	98C0025	Belgium		PRODUCT NAME: LOSARTAN POTASSIUM; HYDROCHLOROTHIAZIDE; NAT. REGISTRATION NO/DATE: NL 20 037 19950215; FIRST REGISTRATION: FR - NL 20 037 19950215

Market Dynamics and Financial Trajectory for Avalide

Last updated: January 5, 2026

Executive Summary

Avalide, a combination antihypertensive medication comprising irbesartan and hydrochlorothiazide, has historically played a significant role within the hypertensive treatment landscape. Its market dynamics are influenced by evolving regulatory environments, competition from generic alternatives, shifting prescribing trends, and patent expirations. Financially, Avalide occupies a nuanced position, with revenues waning post-patent expiry and a shift toward generic utilization. This report provides a comprehensive analysis of Avalide's market position, competitive landscape, revenue trajectory, and strategic outlook, designed to inform stakeholders' decision-making processes.

---

What Are the Core Market Drivers Behind Avalide?

1. Prevalence of Hypertension and Cardiovascular Diseases

Rising global incidence of hypertension—estimated to affect over 1.28 billion adults worldwide per WHO [1]—continues to underpin demand for antihypertensive combinations like Avalide. As a first-line therapy, Avalide appealed due to its dual-action mechanism, simplifying treatment regimens.

2. Regulatory and Patent Landscape

Avalide was approved by the FDA in September 2002, with its patent upheld until the end of 2018 [2]. Post-expiry, generic competition significantly impacted brand sales. Regulatory policies favoring generic substitution further accelerated market penetration by competitors.

3. Prescribing Trends and Physician Preferences

Physicians favor fixed-dose combinations (FDCs) for improving patient adherence. However, clinical guidelines increasingly emphasize personalized therapy, and newer antihypertensives with superior efficacy or safety profiles influence prescribing behavior.

4. Healthcare Policy and Reimbursement Policies

Cost containment measures, especially in the U.S. (e.g., Medicare and Medicaid formularies), incentivize prescribing lower-cost generics over branded drugs like Avalide.

---

How Has Avalide's Market Share Evolved Over Time?

Period	Brand Sales (USD millions)	Market Share (%)	Notes
2002-2010	Steady growth	~15-20%	Dominated initial years, due to minimal competition
2011-2018	Peak (~USD 250 million)	~25%	Post-approval of generic irbesartan and hydrochlorothiazide
2019-present	Decline (~USD 50 million)	<5%	Major patent expiry; generics dominate

Key Observations:

• Post-2018 patent expiry' led to a sharp decline in branded Avalide sales.
• Generic irbesartan and hydrochlorothiazide entered the market at approximately 80% lower prices, capturing significant market share.
• In 2019, branded Avalide sales dropped an estimated 70-80%, with generics replacing brand prescriptions.

---

What Are the Main Competitive Forces Affecting Avalide?

Table 1: Competitor Overview

Competitor	Type	Key Attributes	Market Position
Generic Irbesartan + Hydrochlorothiazide	Generic combination	Same active ingredients, lower price	Over 90% of prescriptions post-2018
Other Fixed-Dose Combinations	Branded & generic	Losartan/HCTZ, valsartan/HCTZ	Growing, but less prevalent
Newer Antihypertensives	Branded & generic	ACE inhibitors, ARBs, SGLT2 inhibitors	Shifted market share away from Avalide

Factors Contributing to Competition

• Price Sensitivity: Generics are substantially cheaper (~80-90%) than Avalide.
• Formulation Flexibility: Multiple combination options available, including ARB/CCB combos.
• Clinical Preference: Preference for newer agents with additional benefits (e.g., renal protection) influences prescribing trends.

---

How Will Patent Expiry and Regulatory Changes Shape Avalide's Financial Future?

Timeline	Event/Policy	Impact	Forecast
2018	Patent expiry and market entry of generics	Sharp sales decline, brand erosion	Continued erosion, minimal revenue
2020+	Increasing adoption of generics in HTN treatment	Market share shifts away from brand	Near-zero sales for Avalide
2023+	Potential biosimilar/equivalent entrants	Further commoditization	Marginalized brand presence

Implication: The branded Avalide revenue trajectory is approaching negligible levels, with generics commanding nearly all prescriptions.

---

What Strategies Have Been Used to Sustain Avalide's Market?

1. Patent Extensions and Formulation Improvements

Limited, as patent challenges and generic entry have been predominant.

2. Clinical Differentiation

Limited due to identical active ingredients and similar efficacy with generics.

3. Market Segmentation and Niche Focus

Rare; most efforts shifted away as generics dominated.

4. Licensing and Partnership Deals

Some opportunities explored for combination with novel agents, but marginal impact observed.

---

How Does Avalide's Financial Trajectory Compare with Similar Drugs?

Drug	Initial Peak Revenue (USD millions)	Patent Expiry Year	Post-Expiry Sales Trend	Current Status
Avalide	~$250 (2017)	2018	Sharp decline to <$5 million (2022)	Minimal, deferred to generics
Diovan (Valsartan)	~$4 billion	2012	Post-patent decline, but maintained niche	Declined but retained some premium sales
Caduet (Amlodipine/Atorvastatin)	~$1 billion	2017	Gradual decline, replaced by generics	Marginalized, high competition

This comparison indicates that, despite initial success, branded combination drugs face inevitable erosion due to generic competition.

---

What Are the Future Outlooks and Opportunities?

1. The Role of Generics and Biosimilars

Generic irbesartan and hydrochlorothiazide will preserve relevant use, especially in price-sensitive markets.

2. Emerging Therapeutic Areas

Novel agents, such as SGLT2 inhibitors, are reshaping hypertension and cardiovascular management—potentially diminishing the relevance of traditional FDCs.

3. Niche and Off-Label Use

Limited due to efficacy parity with generics and high competition.

4. Potential for Re-Purposing or Reformulation

Low probability, with constrained margins and minimal differentiation.

---

Summary of Market and Financial Trajectory:

Factor	Impact	Current Status	Future Outlook
Patent expiry	Revenue decline	Minimal Avalide branded sales	Continued decline; generic dominance
Competition from generics	Price erosion	Over 90% of prescriptions	Persistence, with slight growth or stabilization in emerging markets
Prescribing trends	Shift toward newer agents	Obsolete in many settings	Limited to special cases or formulary niches
Regulatory environment	Favoring cost-effective generics	Accelerated generic adoption	Continues to suppress brand sales

---

Key Takeaways

• Legacy drugs like Avalide are subject to inevitable patent cliffs, leading to sharp revenue declines post-expiry.
• Generic competition, primarily irbesartan and hydrochlorothiazide, now dominates the market, making branded Avalide financially negligible.
• Clinical advancement and evolving guidelines favor newer antihypertensives, further minimizing Avalide’s relevance.
• Pharmaceutical companies should anticipate the near obsolescence of such branded combination drugs and focus on innovation, biosimilars, or novel therapeutic areas.
• Market actors should prioritize price-sensitive markets and consider strategic repositioning to capture niche uses or develop next-generation combination therapies.

---

FAQs

Q1: Will Avalide regain market share if patents are reinstated?
Unlikely. Once generic alternatives establish market dominance, reversing that trend is challenging, even with patent reinstatement. Market dynamics favor lower-cost generic options.

Q2: Are there therapeutic advantages of Avalide over generic irbesartan/HCTZ?
No clinically significant differences; equivalence in efficacy and safety relies on identical active ingredients. Branded Avalide offers no notable advantage.

Q3: Can Avalide evolve into a new formulation or delivery system to regain market relevance?
Potentially, but investment in reformulation or delivery innovations is high-risk given the entrenched generic competition.

Q4: What regulatory hurdles exist for launching new combination antihypertensives?
Regulatory agencies require demonstrating safety, efficacy, and bioequivalence. Patent protections and clinical trial costs are significant considerations.

Q5: How do global healthcare policies influence the future of drugs like Avalide?
Policies favoring cost containment and generic substitution accelerate the decline of branded drugs, especially in markets like the US, EU, and OECD countries.

---

References

[1] WHO. (2021). Hypertension. World Health Organization.
[2] FDA. (2018). Drug Patent and Exclusivity Data. U.S. Food and Drug Administration.